•
Mar 31, 2020
Bridgebio Q1 2020 Earnings Report
Reported financial results for Q1 2020 and provided a business update.
Key Takeaways
BridgeBio Pharma reported its Q1 2020 financial results, ending the quarter with $928.4 million in cash, cash equivalents, and marketable securities. The company is managing the impact of the COVID-19 pandemic on its clinical trials and drug development programs and expects current cash to carry it through critical milestones into 2022.
Ended Q1 2020 with $928.4 million in cash, cash equivalents, and marketable securities.
Working to minimize disruption from COVID-19 on clinical trials and drug development programs.
On track to file its second New Drug Application (NDA) later this year.
Anticipate disclosing new product candidates and filing multiple new INDs in 2020.